Transcript: Vertex Pharmaceuticals Incorporated presents at the 5th Annual Evercore ISI HealthCONx Conference 2022 on November 30, 2022 at 09:15.

    By No Comments2 Mins Read



    Hi. I’m Lisa Bayko, a biotech analyst at Evercore ISI. Welcome to HealthCONx day two. I am very happy to host her amazing 45 minute session with Vertex. And then there’s Stuart Arbuckle…

    S&P Capital IQ 2022

    All news about VERTEX PHARMACEUTICALS

    ANALYST RECOMMENDATIONS FOR VERTEX PHARMACEUTICALS

    Sale 2022 8 934 meters
    –
    –
    net income 2022 3 285 meters
    –
    –
    NetCash 2022 10 628 meters
    –
    –
    PER 2022 24,7x
    Yield 2022 –
    capitalization 81 217 meters
    81 217 meters
    –
    EV / Sale 2022 7,90 times
    EV / Sale 2023 6,95 times
    number of employees 3 900
    free float 99.8%

    Graph VERTEX PHARMACEUTICALS


    Interval:

    Period:




    Vertex Pharmaceuticals Technical Analysis Chart | Market Screener

    Technical Analysis Trends Vertex Pharmaceuticals

    short term Middle term long term
    trend strong strong strong

    Income Statement Evolution

    sell

    buy
    average consensus excellent
    number of analysts 28
    Final closing price 316,40$
    average target price 323,74$
    Spread/Average Target 2,32%




    Source link

    Share.

    Leave A Reply